LOGIN JOIN SHARECAFE SIGN UP FOR OUR NEWSLETTER ADVERTISE
share cafe logo  
 
SHARECAFE COMMENTARY

Flat Outlook At Primary Health
BY GLENN DYER - 24/11/2017 | VIEW MORE ARTICLES BY GLENN DYER

Get More Commentary, Discussion & Market Information On -

PRY - PRIMARY HEALTH CARE LIMITED


In contrast to some of ‘downgrades’ in earnings guidance in recent times Primary Health Care, the pathology and medical centre operator escaped relatively unmarked yesterday after the annual meeting was told earnings this financial year would not be much different to those for 2016-17.

The shares eased 1.6% to $3.50, a big difference to the whacking shares in services and testing group, ALS copped earlier in the week when analysts reckoned the company’s full year guidance was a bit light on compared with market estimates. ALS shares lost more than 15%.

Primary shareholders though escaped that sort of punishment after the meeting was told the opening of new centres and investments in new technology and businesses will dent its performance in the current financial year.

CEO Malcolm Parmenngs woulter told the meeting that the opening of four medical centres and one imaging site will impact Primary’s short-term performance.

He also said there will also be additional costs from the roll-out of technology programs and investments in the company’s Health & Co private medical centres and IVF operations, he said.

While in the first few months of the current financial year so far, GP recruitment has been softer-than-expected, the performance of the pathology business has been solid, but the company’s imaging was performing above last year.

As a result he forecast an underlying profit for the year of between $92 million and $97 million, which compares to a $92.1 million underlying profit in 2016-17.

Citi said in October that consensus analyst estimates of an underlying profit of $97 million were overly optimistic, citing revenue challenges, rising costs in Primary's medical centres division and pathology collection centres, and the loss of a $30 million-per-year cancer screening contract from the second half of 2017/18.

Mr Parmenter said yesterday the loss of the bowel screening contract will not be material to the company in 2017-18, though “will be a headwind in the latter part of the year”.

That’s a hint that the closing months of the June half year could be tougher for Primary than things are now. But yesterday’s meeting was told that the June half is likely to see a stronger profit contribution than the current half year.



View More Articles By Glenn Dyer

Glenn Dyer has been a finance journalist and TV producer for more than 40 years. He has worked at Maxwell Newton Publications, Queensland Newspapers, AAP, The Australian Financial Review, The Nine Network and Crikey.

At the AFR he was a finance writer, Finance Editor, News Editor and Chief of Staff. At the Nine Network he was supervising producer of Business Sunday for more than 16 years. He has also written for other online and analogue print publications here and overseas.



 

RECENTLY ADDED TO SHARECAFE


 › Marcus Today End Of Day Report
 › Tuesday At The Close
 › Brokers Keen On Cleanaway-Tox
 › Cleaner Focus For Gale Pacific
 › Review Of 2017, Outlook For 2018 - Still In The 'Sweet Spot', But Expect More Volatility Ahead
 › Market At Midday On Tuesday
 › Six Reasons To Be Wary Right Now
 › Why A Rise In Rates Won't Mean Much
 › The Quest For Trading Truth
 › How Skyscrapers Predict Market Crashes?
 › Overnight: Crypto Crazy
 › MIN - Morgan Stanley rates the stock as Overweight
 › RAN - Morgans rates the stock as Hold
 › AGL - UBS rates the stock as Buy
More ShareCafe   

GET THE SHARECAFE BREAKFAST BRIEFING


Delivered free to your inbox before the market opens each trading day. Sign up below +

SHARECAFE VIDEO


View More Videos